醫藥股普遍下跌 歌禮、藥明生物、艾美、金斯瑞及三葉草挫5%-10%
內地第三季GDP按年增長放緩至4.9%仍勝預期。恆指現報17,764,反覆微吐8點,總成交額578億元。
醫藥板塊今天普遍下跌,三葉草生物-B(02197.HK)連續五天拾級而下兼屢創上市新低,現報0.61元即市低位,下挫10%。艾美疫苗(06660.HK)六連跌,股價屢創上市新低,午後低見8.76元,現報8.8元,續挫6%。
金斯瑞生物(01548.HK)公佈上季CARVYKTI貿易銷售淨額約1.52億美元。該股今早高開報21.35元欠承接,掉頭倒跌6.4%,報19.76元即市低位,股價一舉失守20天、250天及10天線(20.4-20.8元)。
藍籌中生製藥(01177.HK)、百濟神州(06160.HK)、藥明康德(02359.HK)、騰盛博藥-B(02137.HK)、康希諾(06185.HK)、維亞生物(01873.HK)、由逾三年高高位連吐第二天聯邦製藥(03933.HK)、四環醫藥(00460.HK)、君實(01877.HK)、信達生物(01801.HK)、歌禮制藥(01672.HK)及藍籌藥明生物(02269.HK)跌逾2.5%-5%,後兩者最傷,股價最低見1.71元及46.5元,現報1.72元及47.5元,齊挫逾半成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.